Furthermore, compounds with dual activity against both Fes and Flt3-ITD, such as HG7-92-01, induce apoptotic responses in FLT3-ITD+ AML cell lines and AML patient-derived bone marrow cells, suggesting that this therapeutic approach may be generally effective against a subset of Flt3-ITD+ AML cases. Here, FLT3 is linked to acute myeloid leukemia.